OLMA: Olema Pharmaceuticals, Inc. Company Value to Net Income

Olema Pharmaceuticals, Inc. - graphic logo of issuer OLMA

Olema Pharmaceuticals (OLMA) is developing potential within the oncology niche by creating oral SERDs to combat ER-positive breast cancer. The company's P/E ratio based on net income clearly demonstrates the market valuation dynamics, where -2.80 characterizes this valuation parameter. Management is focused on implementing advanced hormone therapy, although high costs associated with final-stage clinical trials create certain financial risks.

P/E Multiple: Olema Pharmaceuticals (OLMA) for 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for olema.com (OLMA)

- share price and consensus valuation forecast:
Price Olema Pharma|OLMA - Consensus Target
- market capitalization information:
Market Value Olema Pharmaceuticals, Inc.|OLMA - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Olema Pharmaceuticals|OLMA - Book Capitalization|Market Capitalization to Book Value Ratio olema.com|OLMA - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Ratio Olema Pharmaceuticals|OLMA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Olema Pharmaceuticals|OLMA - Company Aggregate Debts|Debts to Book Value Olema Pharma|OLMA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Olema Pharmaceuticals|Immediate Liquidity olema.com
- company profitability and valuation multiples indicators:
OLMA - Company Net Income|Expected Profit Olema Pharmaceuticals|OLMA - P/E Multiple|Projected Price to Earnings Ratio Olema Corp|OLMA - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Olema Pharmaceuticals, Inc.|OLMA - Operating profit EBITDA|Net earnings per share (EPS TTM) Olema Pharmaceuticals|OLMA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months olema.com|OLMA - Earnings per share growth in current year|Net earnings per share change forecast for next year Olema Pharmaceuticals
- company sales and revenue statistics:
OLMA - Revenue and Sales Volume|Company Future Revenue Olema|OLMA - P/S Multiple|Forward P/S Multiple Olema Pharma
Summary company analysis:OLMA (Olema Pharmaceuticals, Inc.)
Product sample of Olema Pharmaceuticals

Investors must filter the risks associated with Olema Pharmaceuticals (OLMA), weighing market value against actual profits to determine the fair value of future earnings. By analyzing the company's weighted average P/E, one can assess how the seamless logistics of climate-controlled drugs translate into capitalization, which helps determine the extent of control major players exert over the valuation of this high-tech and sustainable business.

Analysis of competing companies

PBYI (Puma Biotechnology, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio GLSI (Greenwich LifeSciences, Inc)|ZNTL (Zentalis Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple MGNX (macrogenics.com)|PSTV - Price to Earnings Ratio|Processa Pharmaceuticals - P/E Multiple|EGRX - P/E Multiple